Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Zwirner

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Medicinal Chemistry|May 6, 2026
Darizmetinib (HRX215): A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b/2a Clinical Development, Targeting the Stress Signaling Protein Kinase MKK4Wolfgang Albrecht, Roland Selig, Bent Pfaffenrot, et al.
Journal of Medicinal Chemistry|July 11, 2025
Discovery of the First Highly Selective 1,4-dihydropyrido[3,4-<i>b</i>]pyrazin-3(2H)-one MKK4 InhibitorLeon Katzengruber, Pascal Sander, Stefan Zwirner, et al.
Journal of Medicinal Chemistry|May 22, 2025
A "Ligand First" Approach toward Selective, Covalent JNK2/3 InhibitorsValentin R Wydra, Nicole Plank, Stefan Zwirner, et al.
Neuro-Oncology Advances|November 2, 2020
Experimental glioma with high bHLH expression harbor increased replicative stress and are sensitive toward ATR inhibitionMarilin Sophia Koch, Stefan Czemmel, Felix Lennartz, et al.
Nature Cancer|February 5, 2022
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancerRamona Rudalska, Jule Harbig, Marteinn T Snaebjornsson, et al.
Nature Communications|March 14, 2020
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumoursEllen Brenner, Barbara F Schörg, Fatima Ahmetlić, et al.
Cell|March 15, 2024
First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failureStefan Zwirner, Anan A Abu Rmilah, Sabrina Klotz, et al.
Cancer Cell|September 13, 2017
A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer DevelopmentYannick Boege, Mohsen Malehmir, Marc E Healy, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Medicinal Chemistry|May 6, 2026
Darizmetinib (HRX215): A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b/2a Clinical Development, Targeting the Stress Signaling Protein Kinase MKK4Wolfgang Albrecht, Roland Selig, Bent Pfaffenrot, et al.
Journal of Medicinal Chemistry|July 11, 2025
Discovery of the First Highly Selective 1,4-dihydropyrido[3,4-<i>b</i>]pyrazin-3(2H)-one MKK4 InhibitorLeon Katzengruber, Pascal Sander, Stefan Zwirner, et al.
Journal of Medicinal Chemistry|May 22, 2025
A "Ligand First" Approach toward Selective, Covalent JNK2/3 InhibitorsValentin R Wydra, Nicole Plank, Stefan Zwirner, et al.
Neuro-Oncology Advances|November 2, 2020
Experimental glioma with high bHLH expression harbor increased replicative stress and are sensitive toward ATR inhibitionMarilin Sophia Koch, Stefan Czemmel, Felix Lennartz, et al.
Nature Cancer|February 5, 2022
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancerRamona Rudalska, Jule Harbig, Marteinn T Snaebjornsson, et al.
Nature Communications|March 14, 2020
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumoursEllen Brenner, Barbara F Schörg, Fatima Ahmetlić, et al.
Cell|March 15, 2024
First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failureStefan Zwirner, Anan A Abu Rmilah, Sabrina Klotz, et al.
Cancer Cell|September 13, 2017
A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer DevelopmentYannick Boege, Mohsen Malehmir, Marc E Healy, et al.
Pageof 1